Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Screening for islet-specific autoantibodies can identify individuals at risk for type 1 diabetes (T1D). Despite calls for increased nationwide autoantibody screening efforts, it is unclear how many individuals have participated in screening among people who may benefit from it. Moreover, knowledge and perceptions of autoantibody screening in real-world samples are not well understood.

Methods: We surveyed a sample of individuals (aged 18+ years old) from T1D Exchange Registry with a personal or family history of T1D to assess their self-reported T1D autoantibody knowledge, experiences, and attitudes. Participants belonged to one of three groups: adults with T1D who had a biological child without T1D or future plans for a child (PWD); parents without T1D who had a biological child with T1D and one or more biological children without T1D (Caregivers); and first-degree adult children or siblings to a person with T1D (Relatives). Descriptive analyses (means, standard deviations, frequencies) are presented by participant groups.

Results: A total of 510 participants enrolled in the study. Across groups, participants reported feeling a little to somewhat knowledgeable about autoantibody screening and positive perceptions of autoantibody screening in general. However, few participants had screened their child without T1D (PWDs, 21.94%; Caregivers, 46.30%) or themselves (Relatives, 19.23%). Among those who had screened, participants reported generally positive experiences. Among those who had not screened, many participants were "undecided" about autoantibody screening (PWD, 38.46%; Caregivers, 40.52%; Relatives, 44.44%). Influences reported for participants' decisions to screen, not screen, or their current indecision differed by group: PWDs (21.70%) and Caregivers (26.87%) most often reported self-initiated research as an influence and Relatives reported they had not previously considered screening (48.28%).

Conclusion: Results highlight the need for more accessible information about screening, including real experiences from those who have screened.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410738PMC
http://dx.doi.org/10.1007/s13300-024-01637-zDOI Listing

Publication Analysis

Top Keywords

autoantibody screening
24
t1d biological
12
child t1d
12
t1d
11
screening
10
screening people
8
type 1 diabetes
8
perceptions autoantibody
8
biological child
8
participants reported
8

Similar Publications

Immune-mediated necrotizing myopathy: an emerging disorder.

Neurologia (Engl Ed)

September 2025

Unidad de ELA-Neuromuscular, Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain; IiSGM, Instituto de Investigación Sanitaria Gregorio Marañón.

Objectives: To describe the main features and the clinical management of a cohort of patients with immune-mediated necrotizing myopathy (IMNM).

Methods: We conducted an observational, monocentric, retrospective study of IMNM patients diagnosed in the Neuromuscular Unit of a tertiary hospital in Madrid (Spain) between 2013 and 2021.

Results: Sixteen IMNM cases were diagnosed, with a median age of 71.

View Article and Find Full Text PDF

The changing landscape of primary autoimmune neuropathies.

Nat Rev Neurol

September 2025

Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau (IR SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain.

Autoimmune neuropathies, such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are rare, disabling disorders. Diagnosis, follow-up and treatment of autoimmune neuropathies rely almost exclusively on clinical parameters, and the available therapies, such as intravenous immunoglobulins and corticosteroids, date from >30 years ago. The lack of therapeutic progress in autoimmune neuropathies has resulted from a combination of limited understanding of their pathophysiology, disease heterogeneity and challenges in trial design.

View Article and Find Full Text PDF

Objectives: To describe the prevalence of gastrointestinal (GI) symptoms in systemic sclerosis (SSc) and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement, and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry.

Methods: This cross-sectional analysis included patients fulfilling 2013 ACR/EULAR SSc or VEDOSS criteria. GI involvement was defined as symptoms in at least one GI tract segment and categorized as upper and lower.

View Article and Find Full Text PDF

Background: Myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positivity has been reported in some people with multiple sclerosis (pwMS), posing a diagnostic challenge. However, most studies have been conducted in predominantly Caucasian populations. We aimed to determine the frequency of MOG-IgG in a large, predominantly Asian MS cohort using a validated MOG-IgG assay.

View Article and Find Full Text PDF

Necrotizing autoimmune myopathy (NAM) is an uncommon inflammatory muscle disease marked by progressive weakness and elevated muscle enzymes. In some individuals, it may develop in association with statin use, particularly when specific autoantibodies are present. We report the case of a 65-year-old man who experienced worsening, painless proximal muscle weakness and significant creatine kinase (CK) elevation shortly after resuming statin therapy following a temporary discontinuation.

View Article and Find Full Text PDF